Profile data is unavailable for this security.
About the company
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-38.72m
- Incorporated2009
- Employees43.00
- LocationKALA BIO Inc1167 Massachusetts AvenueARLINGTON 02476United StatesUSA
- Phone+1 (781) 996-5252
- Fax+1 (781) 642-0399
- Websitehttps://www.kalarx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nexgel Inc | 5.01m | -3.39m | 23.69m | 19.00 | -- | 5.31 | -- | 4.73 | -0.5722 | -0.5722 | 0.8464 | 0.6589 | 0.4942 | 3.03 | 6.44 | 263,631.60 | -35.74 | -44.61 | -48.15 | -56.19 | 23.74 | 5.02 | -72.33 | -180.98 | 0.8135 | -- | 0.1992 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| Polypid Ltd | 0.00 | -24.70m | 23.74m | 59.00 | -- | 10.46 | -- | -- | -9.65 | -9.65 | 0.00 | 0.3337 | 0.00 | -- | -- | 0.00 | -107.89 | -76.92 | -164.39 | -89.61 | -- | -- | -- | -- | -- | -24.21 | 0.8425 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
| Tonix Pharmaceuticals Holding Corp | 12.46m | -149.01m | 25.06m | 103.00 | -- | 0.0328 | -- | 2.01 | -110.99 | -110.99 | 6.16 | 4.28 | 0.1083 | 0.8436 | -- | 120,951.50 | -129.55 | -59.46 | -157.22 | -65.92 | 21.59 | -- | -1,196.12 | -5,126.73 | 0.7181 | -- | 0.1678 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
| Natural Alternatives International, Inc. | 113.80m | -7.22m | 27.15m | 296.00 | -- | 0.3288 | -- | 0.2386 | -1.23 | -1.23 | 19.38 | 13.32 | 0.7676 | 3.96 | 9.52 | 384,445.90 | -4.87 | 2.33 | -5.61 | 2.80 | 6.03 | 14.24 | -6.34 | 2.06 | 1.59 | -10.21 | 0.1326 | 0.00 | -26.11 | -3.82 | -386.16 | -- | -10.75 | -- |
| BioXcel Therapeutics Inc | 2.40m | -107.83m | 29.33m | 74.00 | -- | -- | -- | 12.20 | -3.56 | -3.56 | 0.074 | -1.84 | 0.0234 | 0.5941 | 3.87 | 32,472.97 | -104.93 | -74.57 | -150.29 | -84.06 | 43.07 | -- | -4,487.39 | -32,300.74 | 2.25 | -10.10 | 3.59 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| KALA BIO Inc | 0.00 | -38.72m | 34.10m | 43.00 | -- | 2.48 | -- | -- | -13.95 | -13.95 | 0.00 | 2.98 | 0.00 | -- | -- | 0.00 | -60.45 | -57.83 | -78.16 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -11.36 | 0.7174 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
| Opus Genetics Inc | 16.45m | -14.11m | 36.78m | 14.00 | -- | 0.748 | -- | 2.24 | -0.5507 | -0.5507 | 0.6871 | 1.56 | 0.3726 | -- | 6.53 | 1,174,929.00 | -31.95 | -58.31 | -36.01 | -65.94 | -- | -- | -85.75 | -137.92 | -- | -10.80 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| Dare Bioscience Inc | 2.84m | -7.20m | 38.25m | 23.00 | -- | 14.08 | -- | 13.47 | -1.07 | -1.07 | 0.3579 | 0.3126 | 0.1213 | -- | 3.85 | 123,462.20 | -30.76 | -109.51 | -191.39 | -246.26 | 0.8477 | -- | -253.60 | -1,104.55 | -- | -- | 0.00 | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| Earth Science Tech Inc | 20.30m | 1.98m | 38.63m | 32.00 | 19.56 | 12.20 | 18.01 | 1.90 | 0.0064 | 0.0064 | 0.0658 | 0.0103 | 5.40 | 36.44 | -- | 634,456.90 | 52.57 | -37.98 | 77.89 | -- | 69.40 | 63.87 | 9.74 | -15.48 | 1.24 | 3.57 | 0.0261 | -- | 24,526.37 | 73.03 | 322.25 | -- | -- | -- |
| Eyenovia Inc | 31.41k | -37.28m | 40.10m | 57.00 | -- | -- | -- | 1,276.53 | -0.7897 | -0.7897 | 0.0007 | -0.0425 | 0.0013 | -- | 0.0418 | 551.05 | -154.24 | -80.31 | -262.28 | -117.70 | -1,489.11 | -- | -118,693.60 | -680.95 | 0.267 | -40.92 | 1.20 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
| Lexaria Bioscience Corp | 411.01k | -4.85m | 40.32m | 5.00 | -- | 3.61 | -- | 98.09 | -0.4455 | -0.4455 | 0.0408 | 0.6403 | 0.0539 | -- | 2.16 | 82,202.00 | -63.85 | -95.67 | -65.93 | -96.58 | 98.83 | 76.98 | -1,185.15 | -1,612.76 | -- | -64.96 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| Verrica Pharmaceuticals Inc | 9.21m | -84.99m | 43.86m | 100.00 | -- | -- | -- | 4.76 | -1.83 | -1.83 | 0.1979 | -0.7467 | 0.1416 | 1.67 | 4.67 | 92,100.00 | -130.68 | -55.75 | -174.03 | -78.33 | 74.08 | -- | -922.81 | -754.94 | 1.22 | -10.16 | 3.82 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| CEL-SCI Corp | 0.00 | -29.10m | 44.28m | 43.00 | -- | 4.61 | -- | -- | -0.5806 | -0.5806 | 0.00 | 0.1562 | 0.00 | -- | -- | -- | -100.88 | -70.19 | -124.78 | -78.31 | -- | -- | -- | -15,434.15 | 0.1793 | -36.79 | 0.5517 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
Data as of Nov 12 2024. Currency figures normalised to KALA BIO Inc's reporting currency: US Dollar USD
35.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 30 Jun 2024 | 891.34k | 19.35% |
| Adar1 Capital Management LLCas of 30 Jun 2024 | 306.07k | 6.64% |
| UBS O'Connor LLCas of 30 Jun 2024 | 147.55k | 3.20% |
| Millennium Management LLCas of 30 Jun 2024 | 142.28k | 3.09% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 49.45k | 1.07% |
| Virtu Americas LLCas of 30 Jun 2024 | 31.10k | 0.68% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 21.36k | 0.46% |
| Stanford Management Co.as of 30 Jun 2024 | 21.13k | 0.46% |
| Geode Capital Management LLCas of 30 Jun 2024 | 18.89k | 0.41% |
| Sassicaia Capital Advisers LLCas of 30 Jun 2024 | 12.00k | 0.26% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
